Zai Lab

Zai Lab Debt

The Debt of Zai Lab (9688.HK) as of Nov 20, 2026 is 224.26 M USD. In the previous year, Debt was 153.47 M USD — a change of 46.12% (higher).

Debt

224.26 MUSD

YoY

46.12%

Last updated:

In 2025, Zai Lab's total debt was 224.26 M USD, a 46.12% change from the 153.47 M USD total debt recorded in the previous year.

The Zai Lab Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
3.64 M USD
Jan 1, 2019
21.78 M USD
Jan 1, 2020
18.60 M USD
Jan 1, 2021
15.54 M USD
Jan 1, 2022
20.39 M USD
Jan 1, 2023
15.15 M USD
Jan 1, 2024
153.47 M USD
Jan 1, 2025
224.26 M USD
The Zai Lab Debt history
YEARDebtYoY
224.26 MUSD+46.12%
153.47 MUSD+912.94%
15.15 MUSD-25.70%
20.39 MUSD+31.23%
15.54 MUSD-16.44%
18.60 MUSD-14.60%
21.78 MUSD+497.87%
3.64 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd. focuses on discovering, developing, and commercializing proprietary therapeutics for unmet medical needs in China, particularly in oncology, autoimmune, and infectious diseases. The company's pipeline includes drug candidates such as Niraparib (ZL-2306), ZL-2103, and ZL-1101, which are in various stages from discovery to late-stage clinical programs. Its products target large patient segments requiring innovative treatments within the Chinese healthcare market. The firm's revenue comes from the commercialization of its proprietary drug candidates, which are developed through internal research and strategic partnerships. Zai Lab Ltd. serves the Chinese biopharmaceutical market, targeting healthcare providers, hospitals, and patients seeking advanced therapies for conditions like cancer and autoimmune disorders. The company leverages its pipeline to generate sales through pharmaceutical distribution channels in China. Zai Lab is one of the most popular companies on Eulerpool.

Debt Details

Understanding Zai Lab's Debt Structure

Zai Lab's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Zai Lab's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Zai Lab’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Zai Lab’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Zai Lab stock

Debt of Zai Lab is 224.26 M USD in 2025.

Debt of Zai Lab changed from 153.47 M USD to 224.26 M USD, representing a 46.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Zai Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zai Lab

All Key Metrics — Zai Lab